Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2026 to 2040 of 7677 results

  1. Pancreas SABR

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  2. Electrically-stimulated intravesical chemotherapy for non-muscle invasive bladder cancer

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  3. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]

    Awaiting development [GID-TA11025] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    Awaiting development [GID-TA11092] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]

    Awaiting development [GID-TA11094] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]

    Awaiting development [GID-TA11099] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]

    Awaiting development [GID-TA11101] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Children and young people with disabilities and severe complex needs: integrated health and social care support

    Awaiting development [GID-QS10146] Expected publication date: TBC

    Quality standard
    Awaiting development

  9. Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care

    Awaiting development [GID-QS10144] Expected publication date: TBC

    Quality standard
    Awaiting development

  10. Pelvic floor dysfunction

    Awaiting development [GID-QS10129] Expected publication date: TBC

    Quality standard
    Awaiting development

  11. Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]

    Awaiting development [GID-TA11466] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Secukinumab biosimilar for treating plaque psoriasis TSID 11992

      Status ...

    Technology appraisal guidance
    Topic selection

  13. Zavegepant for treating acute migraine TSID 11998

    Awaiting development [GID-TA11527] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995

    Awaiting development [GID-TA11525] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996

    Awaiting development [GID-TA11526] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development